{"id":1019468,"date":"2026-11-10T11:20:53","date_gmt":"2026-11-10T16:20:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/"},"modified":"2026-11-10T11:20:53","modified_gmt":"2026-11-10T16:20:53","slug":"esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/","title":{"rendered":"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ANN ARBOR, Mich., Nov.  10, 2026  (GLOBE NEWSWIRE) &#8212; Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Aurobindo Pharma Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Aurobindo in response to Aurobindo\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Aurobindo has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.<\/p>\n<p>The pending patent litigation against the remaining defendants (MSN Pharmaceuticals Inc. (along with an affiliate); and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and\/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.<\/p>\n<p>\n        <strong>Esperion Therapeutics<\/strong><br \/>\n        <br \/>Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare\/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.<\/p>\n<p>With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CYlynI1JgiBNOs6Sudw3xZlPD4oHwHd7x7y57WeAOdVEeaAka456GshesyozjD9M6mOAD7ZkvvFANH70B5PQSw==\" rel=\"nofollow\" target=\"_blank\"><u>esperion.com<\/u><\/a> and follow Esperion on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rOote_TciIHRd7XwVeJvl6_bjAZz8QtdfdCgP15-si4cgGuzq89nSLdqfF9x6iTNqOhhgp_o2LIqrPMWyGSegWuOkH0r2UAg80-b3COs5YX1WB_6Lk6DCUzdtrxd5DRp\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vvaNr_K10QXQ1nyCP8G2cZalDWaWr9S5ZC2wVPE2vBIKRJAw40OhO9AKBoQyPnE_PoYojNyBT4O4xfVFS9xUNg==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>.<\/p>\n<p>\n        <strong>About ARCHIMED<\/strong><br \/>\n        <br \/>With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal &amp; Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools &amp; Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages \u20ac9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EUR\u00caKA Foundation. For more information about ARCHIMED, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mxAQJ9RN0ALTm51GwUno1iX71mwWBuegsNsS1um1cPChkz2O2w39FKcQ2b4BwRX8W_M7MAQhgi6IPKSvpl7FymjwkiLEqhpj8Mgf6Y09xVQ=\" rel=\"nofollow\" target=\"_blank\">www.ARCHIMED.group<\/a>.<\/p>\n<p>\n        <strong>Esperion Contact Information:<\/strong><br \/>\n        <br \/>Media: <br \/>Tiffany Aldrich <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zcXrhRXUyz6hNlYVmvbx0kU2C-DVadFTURWEPJ28I-T-4MpeHzCMnu35pyZUOiwkIvCJpIkbh-VXyxdND5FC7WxXY4BGcFP1c4ziXULRQb5plx9y8ORx2lIntopb4xqS\" rel=\"nofollow\" target=\"_blank\">corporateteam@esperion.com<\/a><br \/>(616) 443-8438<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDc4YzdmNjUtYjY4Yi00NzI2LTk0OWQtYWEyNmFjOGExODFiLTEwMTg3MTQtMjAyNi0xMS0xMC1lbg==\/tiny\/Esperion-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ANN ARBOR, Mich., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Aurobindo Pharma Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Aurobindo in response to Aurobindo\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Aurobindo has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (MSN Pharmaceuticals &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019468","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ANN ARBOR, Mich., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Aurobindo Pharma Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Aurobindo in response to Aurobindo\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Aurobindo has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (MSN Pharmaceuticals &hellip; Continue reading &quot;Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T16:20:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040\",\"datePublished\":\"2026-11-10T16:20:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/\"},\"wordCount\":456,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/\",\"name\":\"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=\",\"datePublished\":\"2026-11-10T16:20:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/","og_locale":"en_US","og_type":"article","og_title":"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040 - Market Newsdesk","og_description":"ANN ARBOR, Mich., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Aurobindo Pharma Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Aurobindo in response to Aurobindo\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Aurobindo has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (MSN Pharmaceuticals &hellip; Continue reading \"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-10T16:20:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040","datePublished":"2026-11-10T16:20:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/"},"wordCount":456,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/","name":"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=","datePublished":"2026-11-10T16:20:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDM0MSM3OTU3MDQ2IzIwMDcxNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-seventh-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) &amp; NEXLIZET\u00ae (bempedoic acid &amp; ezetimibe) Prior to April 19, 2040"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019468"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}